Close

Jump to:

  • Navigation
  • Content
  • Footer
TrackActive hero image

TrackActive

Follow

A chatbot-driven physical health app, empowering people to take care of their musculoskeletal health.

100%
 - 
Funded 8 Apr 2019
£250,000 target
£253,598 from 278 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website www.trackactiveme.com
Sectors Healthcare Digital B2B
Company number 10530672
Incorporation date 17 Dec 2016
More
Less

Investment summary

Type Equity
Valuation (pre-money) £1.7M
Equity offered 12.70%
Tax relief

EIS

Co investor HR tech partnership

Funding & Innovation specialists in the ‘People Digital Tech start-up’ area

  • Idea
  • Team
  • Updates
  • Investors 278
  • Discussion
  • Documents

Idea

Introduction

Our vision is to empower millions of people to take care of their musculoskeletal health, including bone, muscle, joint and spine conditions. TrackActive Me is an application that allows people to self-manage their musculoskeletal conditions and facilitate better health through exercise.

Via a chatbot, TrackActive Me assesses a person’s current and past musculoskeletal conditions, and their overall health and exercise habits. Our AdaptX technology is a combination of clinical algorithms, artificial intelligence, and exercise rehabilitation data, sourced from our clinical exercise software, TrackActive Pro. This technology designs and delivers personalised advice and exercise programmes, which adapt as a user progresses.

TrackActive Me is a highly scalable application distributed through insurance, corporate, and public health partners. Organisations are provided with an administration dashboard which aggregates the anonymised data to display an overview of the physical health of their customers or employees.

Intended impact

Musculoskeletal conditions are a significant burden on healthcare systems and economies, with spinal pain being the leading cause of global disability since 1990. It has been estimated that up to 50% of people have a musculoskeletal condition and two thirds of office employees experience pain in the neck, back or upper limb.

In 2015, an estimated 22% of UK people chose to self-diagnose, with ‘back pain’ being the leading healthcare Google search. Yet it appears only around 3 out of the top 10 health information search results provide information that is highly useful.

Evidence demonstrates that appropriate exercise and advice improves and prevents many musculoskeletal conditions. We believe TrackActive Me is the product to provide this.

In our view, there is a distinct opportunity in the market due to a lack of quality self-care musculoskeletal applications. For example, within the NHS Apps Library, there are no musculoskeletal applications compared with 18 mental health applications.

We aim to reach our intended market by distributing TrackActive Me via health and life insurance companies and within corporate health and wellbeing programmes. Through our commercial agreements we aim to reach over 500,000 people within one year.

Substantial accomplishments to date

TrackActive was founded by Ian Prangley and Michael Levens.

Ian is a sports physiotherapist, strength and conditioning specialist, and professional tennis coach, having worked for the Australian Institute of Sport and independently with various elite athletes, including Britain’s number 1 tennis player, Kyle Edmund. He is a physiotherapy consultant at the Centre for Health and Human Performance, Harley St, London, has conducted award-winning physiotherapy research, and was a guest author in an Amazon bestselling textbook, ‘Sports Injury Prevention and Rehabilitation’. Ian holds an MBA in addition to Masters degrees in both Sports Physiotherapy and Exercise Science.

Michael is a technology entrepreneur with 16 years experience in delivering digital transformation projects for corporates and startups in the UK and internationally. This is complimented by a diverse educational background in Information Technology (1st Class Honours) combined with postgraduate business studies at London Business School and University of Cambridge. Previously, Michael competed on the professional tennis circuit.

Michael and Ian are well supported by a talented product development team based in Poland and a group of highly experienced advisors covering core areas of the business.

TrackActive was initially funded by the founders and is now supported by TrackActive Pro subscription and content licensing revenue. Since 2015, the team has achieved the following:

Monetisation strategy

TRACKACTIVE ME:

We charge organisations an annual licensing fee based on

• Number of end users
• Chosen access level to data insights
• Required customisations

We are focused on having TrackActive Me adopted by corporates and insurers with an aim to reduce direct and indirect costs of musculoskeletal disorders and to increase their customer and employee satisfaction. Our strategy for growing our customer base is through direct contact and via distribution partnerships.

Direct:

• Key direct partnership with Insurance Australia Group established in June 2018.
• Direct access to corporates and insurers through the Startupbootcamp InsurTech alumni, Sport England’s Open Active accelerator, DigitalHealth.London accelerator and our established networks.

Distribution Partnerships:

• Key channel partnership with General Reinsurance Group established in October 2017.
• Global partnerships with employee health benefit providers, reinsurance companies and insurance-related product providers.

TRACKACTIVE PRO:

Private health clinics pay a monthly subscription starting from £25 per month, which scales depending on the number of health practitioners. We also provide content licensing of evidence-based exercise videos, images and descriptions.

Use of proceeds

Self-funded to date by the two founders, there is a short-term funding requirement to supplement existing revenue (paid pilots, TrackActive Pro subscriptions and content licensing sales) prior to generating TrackActive Me licensing revenue.

Initial focus will be on business development activities to secure further commercial partnerships, continued development of TrackActive, and generating evidence of efficacy. Evidence generation may involve commercial pilots, university-led research, and owning, acquiring, or partnering with a health clinic.

The following breakdown shows how we intend to allocate funds:

• 50% Product Development (product upgrades, Android release, administration dashboard, health content production).
• 40% Marketing (business development, evidence generation, and marketing activities for further customer acquisition).
• 10% Operations.

Advance Assurance for EIS was granted on the 20th of June 2017.

NOTICE

Please note, TrackActive consists of a UK parent company (Active Health Tech Limited), and a wholly owned Australian subsidiary company (Active Health Tech Pty Ltd). Seedrs investors will be investing in the UK parent company.

The UK company currently has outstanding directors' loans amounting to £12,078. The Australian company has total outstanding directors' loans amounting to AUS $35,744.42. All directors' loans accrue no interest and are only repayable from the company's free cashflow, investor funds will not be used to repay these loans.

Open an account to get access to the team members of TrackActive

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for TrackActive has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 25 January 2019 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £1,726,346

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel